Compare · ABT vs PRGO
ABT vs PRGO
Side-by-side comparison of Abbott Laboratories (ABT) and Perrigo Company plc (PRGO): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ABT and PRGO operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- ABT is the larger of the two at $153.99B, about 108.6x PRGO ($1.42B).
- Over the past year, ABT is down 33.5% and PRGO is down 61.3% - ABT leads by 27.9 points.
- PRGO has been more active in the news (15 items in the past 4 weeks vs 9 for ABT).
- ABT has more recent analyst coverage (25 ratings vs 11 for PRGO).
- Company
- Abbott Laboratories
- Perrigo Company plc
- Price
- $88.42-0.03%
- $10.25+0.89%
- Market cap
- $153.99B
- $1.42B
- 1M return
- -0.48%
- -3.44%
- 1Y return
- -33.46%
- -61.34%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NYSE
- IPO
- News (4w)
- 9
- 15
- Recent ratings
- 25
- 11
Abbott Laboratories
Abbott Laboratories discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The Established Pharmaceutical Products segment provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon. The Diagnostic Products segment offers laboratory systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion; molecular diagnostics systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, as well as detect and measure infectious agents; point of care systems; cartridges for testing blood; rapid diagnostics lateral flow testing products; molecular point-of-care testing for HIV, SARS-CoV-2, influenza A and B, RSV, and strep A; cardiometabolic test systems; drug and alcohol test, and remote patient monitoring and consumer self-test systems; and informatics and automation solutions for use in laboratories. The Nutritional Products segment provides pediatric and adult nutritional products. The Medical Devices segment offers rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases; and diabetes care products, as well as neuromodulation devices for the management of chronic pain and movement disorders. The company was founded in 1888 and is based in North Chicago, Illinois.
Perrigo Company plc
Perrigo Company plc provides over-the-counter (OTC) health and wellness solutions that enhance individual well-being by empowering consumers to prevent or treat conditions that can be self-managed. The company operates through Consumer Self-Care Americas, Consumer Self-Care International, and Prescription Pharmaceuticals segments. The Consumer Self-Care Americas segment focuses primarily on the development, manufacture, marketing, and sale of store brand, self-care products in categories, including upper respiratory, pain and sleep-aids, digestive health, nutrition, vitamins, minerals and supplements, healthy lifestyle, skincare and personal hygiene, and oral self-care in the United States, Mexico, Canada, and South America. The segment offers its products under the brand names of Prevacid 24HR, Good Sense, Zephrex D, ScarAway, Plackers, Rembrandt, Steripod, Firefly, REACH, and Dr. Fresh. The Consumer Self-Care International segment develops, manufactures, markets, and distributes consumer self-care brands through a network of pharmacies, wholesalers, drug and grocery store retailers, and para-pharmacies in approximately 30 countries, primarily in Europe. The Prescription Pharmaceuticals segment develops, manufactures, and markets a portfolio of generic prescription drugs, such as creams, ointments, lotions, gels, shampoos, foams, suppositories, sprays, liquids, suspensions, solutions, controlled substances, injectable, hormones, oral solid dosage forms, and oral liquid formulations in the United States, as well as pharmaceutical and diagnostic products in Israel. In addition, it offers contract manufacturing services. Perrigo Company plc was founded in 1887 and is headquartered in Dublin, Ireland.
Latest ABT
- Director Stratton John G bought $173,640 worth of Common shares without par value (2,000 units at $86.82), increasing direct ownership by 9% to 23,319 units (SEC Form 4)
- SEC Form 11-K filed by Abbott Laboratories
- Abbott declares 410th consecutive quarterly dividend
- New research shows even stronger health outcomes for participants in a 'Food is Medicine' program when paired with support from community health workers
- New Abbott data show many people with diabetes may not recognize symptoms of diabetic ketoacidosis
- SEC Form SD filed by Abbott Laboratories
- Abbott secures CE Mark for world's first dual glucose-ketone sensing technology for people with diabetes
- ACS guideline reaffirms Abbott leadership in noninvasive colorectal cancer screening
- Abbott showcases expanding evidence across its cancer diagnostics portfolio at ASCO 2026
- SEC Form 4 filed by EXECUTIVE VICE PRESIDENT Moreland Mary K
Latest PRGO
- Director Parker Geoffrey M. exercised 976 units of Ordinary Shares at a strike of $10.99 and covered exercise/tax liability with 469 units of Ordinary Shares, increasing direct ownership by 2% to 33,217 units (SEC Form 4)
- SEC Form 4 filed by Interim President and CEO Manzone Albert
- Director Alford Bradley A exercised 976 units of Ordinary Shares at a strike of $10.99 and covered exercise/tax liability with 469 units of Ordinary Shares, increasing direct ownership by 1% to 45,465 units (SEC Form 4)
- SEC Form SD filed by Perrigo Company plc
- Former CEO and director Lockwood-Taylor Patrick exercised 25,230 units of Ordinary Shares at a strike of $10.83 and covered exercise/tax liability with 12,906 units of Ordinary Shares, increasing direct ownership by 11% to 123,170 units (SEC Form 4)
- Perrigo Company plc filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure
- Perrigo Announces Leadership Transition
- EVP and President of CSCI Khoury Roberto exercised 17,902 units of Ordinary Shares at a strike of $10.83 and covered exercise/tax liability with 9,346 units of Ordinary Shares, increasing direct ownership by 164% to 13,761 units (SEC Form 4)
- EVP & CHRO Willis Robert exercised 3,441 units of Ordinary Shares at a strike of $10.83 and covered exercise/tax liability with 1,797 units of Ordinary Shares, increasing direct ownership by 3% to 50,568 units (SEC Form 4)
- EVP and CSO Lennox Abigail exercised 3,823 units of Ordinary Shares at a strike of $10.83 and covered exercise/tax liability with 1,996 units of Ordinary Shares, increasing direct ownership by 66% to 4,607 units (SEC Form 4)